Senior Director, Search & Evaluation Late TA Lead, Immunology

CSL Vifor; Glattbrugg; Hybrid; CHF 250.000 - 350.000; Vollzeit

Zusammenfassung

CSL Vifor is seeking a Senior Director of Search & Evaluation to shape the Immunology portfolio by leading late-stage external assets sourcing and evaluation.

Hybrid onsite 3 days per week across Zurich, Maidenhead, Waltham, or King of Prussia hubs. Requires deep Immunology expertise, KOL engagement, and cross-functional due diligence to drive strategic partnerships.

Qualifikationen

• 15+ years in biopharma with clinical development/external innovation or BD.
• Advanced degree required (MD, PhD, or equivalent).
• Deep Immunology clinical expertise and late-stage deal experience.

Aufgaben

• Lead sourcing for Phase 2 to marketed Immunology assets.
• Influence strategy and integrate external priorities into portfolio planning.
• Co-lead NPO prioritization with cross-functional teams.
• Engage KOLs and investigators to validate asset potential.
• Coordinate due diligence across clinical, regulatory, and commercial domains.
• Partner with BD and Ecosystem Leads to advance opportunities.
• Represent the TA at conferences and build pharma/biotech networks.

Kenntnisse

Strategic sourcing

External innovation

KOL engagement

Cross-functional leadership

Portfolio strategy

Ausbildung

MD/PhD or equivalent

Jobbeschreibung

CSL is expanding its external innovation capability, and we're looking for a Senior Director of Search & Evaluation to help shape the future of our Immunology portfolio.

We are seeking a Senior Director of Search & Evaluation to lead strategic sourcing and evaluation of later-stage external clinical assets in Immunology. This leader will focus on opportunities from Phase 2 through marketed drugs, requiring deep clinical expertise, strong engagement with external Key Opinion Leaders (KOLs) and clinical investigators, and a keen understanding of evolving standards of care. The role is critical to shaping our portfolio through high-impact partnerships and transactions.

To be hybrid-based onsite (3 days a week) at one of our R&D hub sites: Zurich (CH), Maidenhead (UK), Waltham (US), King of Prussia (US). This position cannot be held remotely

Main Responsibilities & Accountabilities

• Serve as the senior S&E leader within the Therapy Area Leadership Team, influencing therapeutic strategy and integrating late-stage external innovation priorities into portfolio planning.

• Lead proactive sourcing efforts for Phase 2 to marketed assets, identifying opportunities that align with TA strategy and unmet medical needs.

• Co-lead internal meetings (with Early Search Lead) focused on evaluating and prioritizing New Product Opportunities (NPOs) within Immunology. NPO meetings are strategic checkpoints where cross-functional teams review potential assets identified by Search and decide whether to advance them for further due diligence and deal negotiations.

• Engage extensively with external KOLs, clinical investigators, and networks to validate asset potential, understand trial designs & clinical endpoints, and anticipate competitive dynamics.

• Maintain deep awareness of changing standards of care and competitive landscapes to inform sourcing priorities and deal strategy.

• Drive cross-functional due diligence for late-stage assets, coordinating clinical, regulatory, commercial, and market access assessments to support governance decisions.

• Partner closely with BD and Regional Ecosystem Leads to advance high-priority opportunities through negotiation and deal close, ensuring seamless handoff and execution

• Represent the TA externally, leading sourcing activities at specialized conferences and building relationships with pharma, biotech, and clinical communities.

Qualifications & Experience Requirements

• 15+ years in biopharma with significant experience in clinical development, external innovation, or business development.

• Advanced degree required (MD, PhD, or equivalent).

• Deep clinical expertise in Immunology

• Proven track record of sourcing and closing late-stage deals and engaging with KOLs and clinical networks.

• Strong understanding of regulatory pathways, market access, and competitive standards of care.